share_log

Cantor Fitzgerald Reiterates Overweight on ADMA Biologics, Maintains $20 Price Target

Cantor Fitzgerald Reiterates Overweight on ADMA Biologics, Maintains $20 Price Target

康泰爾費茨傑拉重申對adma biologics的超配評級,維持20美元的目標股價
Benzinga ·  09/20 11:10  · 評級/大行評級

Cantor Fitzgerald analyst Kristen Kluska reiterates ADMA Biologics (NASDAQ:ADMA) with a Overweight and maintains $20 price target.

Cantor Fitzgerald分析師Kristen Kluska重申了adma biologics(納斯達克:ADMA)的超重,並維持了20美元的目標價格。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論